Elbit Medical Imaging, Ltd.
Gamida-Cell, Teva to develop and commercialize StemEx for leukemia
Published in Law and Health Weekly, April 2nd, 2005
Elbit Medical Imaging, Ltd., (EMITF) (EMI) has been advised by its subsidiary company, Elscint, Ltd., (ELT), in which EMI holds approximately 61%, that Teva Pharmaceutical Industries, Ltd., (TEVA) has exercised its option to enter into a joint venture with Gamida-Cell, Ltd., in which Elscint (through a wholly owned subsidiary) holds 29.2% on a fully diluted basis, in order to develop and commercialize StemEx for the treatment of leukemia and lymphoma.
Gamida-Cell is focused on the expansion of hematopoietic (blood) stem-cell therapeutics in clinical development for cancer and autoimmune diseases, as well as future regenerative cell-based medicines including cardiac and...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Advanced Magnetics, Inc.
Joseph L. Farmer named general counsel at pharmaceutical calls - Advanced Neuromodulation Systems
Promising results reported in depression research study - Avitar, Inc.
Diagnostics company participates in TISPOL project - Genzyme Corp.
American Kidney Fund teams with biotech firm for Renagel assistance plan - Healthcare Costs
Aetna to become national provider of Medicare prescription drug plans - Healthcare Funding
Tennessee Governor's options: cut TennCare drugs or education by $268 million - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
